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Abstract
Background: Macrophage migration inhibitory factor (MIF) has emerged as a pivotal mediator of innate immunity and has
been shown to be an important effector molecule in severe sepsis. Melioidosis, caused by Burkholderia pseudomallei, is an
important cause of community-acquired sepsis in Southeast-Asia. We aimed to characterize the expression and function of
MIF in melioidosis.
Methodology and Principal Findings: MIF expression was determined in leukocytes and plasma from 34 melioidosis
patients and 32 controls, and in mice infected with B. pseudomallei. MIF function was investigated in experimental murine
melioidosis using anti-MIF antibodies and recombinant MIF. Patients demonstrated markedly increased MIF mRNA
leukocyte and MIF plasma concentrations. Elevated MIF concentrations were associated with mortality. Mice inoculated
intranasally with B. pseudomallei displayed a robust increase in pulmonary and systemic MIF expression. Anti-MIF treated
mice showed lower bacterial loads in their lungs upon infection with a low inoculum. Conversely, mice treated with
recombinant MIF displayed a modestly impaired clearance of B. pseudomallei. MIF exerted no direct effects on bacterial
outgrowth or phagocytosis of B. pseudomallei.
Conclusions: MIF concentrations are markedly elevated during clinical melioidosis and correlate with patients’ outcomes. In
experimental melioidosis MIF impaired antibacterial defense.
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Introduction
Macrophage migration inhibitory factor (MIF) was one of the
first cytokines to be discovered almost half a century ago [1–4].
Since then MIF has emerged as a pivotal mediator of innate
immunity in various inflammatory diseases such as rheumatoid
arthritis and atherosclerosis [5,6] and is considered to be an
integral component of the host antimicrobial alarm system [4,7].
MIF, a classical proinflammatory cytokine, is constitutively
expressed by many tissues with environmental contact such as
the lung and the gastrointestinal tract, and by numerous cell
types, among others T- and B-lymphocytes, monocytes and
macrophages [4]. MIF-deficient macrophages are hyporespon-
sive to lipopolysaccharide (LPS) due to a down-regulation of
Toll-like receptor (TLR)-4 [8,9]. In line, MIF knockout mice
were resistant to LPS induced toxic shock [8–10]. Recently it
was shown that blood concentrations of MIF are elevated in
patients with sepsis and able to predict early mortality [11–14].
Similarly, MIF is increased in patients with meningococcal
disease and highest in the presence of shock [15]. Excitingly,
treatment with anti-MIF antibodies protected mice from lethal
peritonitis induced by Escherichia coli or cecal ligation and
puncture (CLP) [16]. Furthermore, ISO-1 and OXIM-11, new
small molecule inhibitors of MIF, offered significant protection
to mice from CLP-induced sepsis [17,18]. These data identified
MIF as a potential mediator of lethality following abdominal
sepsis.
In Southeast-Asia and Northern-Australia the gram-negative
bacillus Burkholderia pseudomallei is an important cause of commu-
nity-acquired sepsis [19,20]. More than half of these cases of
melioidosis, as this severe infection is named, habitually presents
with pneumonia, frequently associated with bacterial dissemina-
tion to distant sites [19–21]. In the present study we aimed to
characterize the expression and function of MIF in melioidosis.
For this we analysed MIF expression patterns in patients with
melioidosis and in a mouse model of B. pseudomallei infection. MIF
function was investigated in experimental murine melioidosis using
anti-MIF antibodies and recombinant MIF.
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Methods
Ethics statement
The patient study was approved by both the Ministry of Public
Health, Royal Government of Thailand and the Oxford Tropical
Research Ethics Committee, University of Oxford, England. We
obtained written informed consent from all subjects before the
study. The Animal Care and Use of Committee of the University
of Amsterdam approved all murine experiments.
Patients
We included 34 individuals with sepsis caused by B. pseudomallei
and 32 healthy controls in this study. Individuals were recruited
prospectively at Sapprasithiprasong Hospital, Ubon Ratchathani,
Thailand in 2004. Sepsis due to melioidosis was defined as culture
positivity for B. pseudomallei from any clinical sample plus a systemic
inflammatory response syndrome (SIRS) [22]. Study design and
subjects have been described in detail [23].
Human plasma MIF and MIF mRNA measurements
Human MIF was measured by ELISA, as described elsewhere
[24]. In addition, MIF mRNA levels were measured as follows.
Heparin blood samples were drawn from an antecubital vein and
immediately put on ice. Leukocytes were isolated using erylysis
buffer, dissolved in Trizol and stored at –80uC. Thereafter, RNA
was isolated and analyzed by multiplex ligation-dependent probe
amplification (MLPA) as described [25,26] (MRC-Holland,
Amsterdam, the Netherlands). Levels of mRNA were expressed
as a normalized ratio of the peak area divided by the peak area of
the b2 microglobulin (B2M) gene [25].
Murine melioidosis
Male C57BL/6 mice (age 8–10 weeks) were purchased from
Harlan Sprague Dawley Inc. (Horst, The Netherlands). Age-
matched animals were used in each experiment. For the
inoculum, B. pseudomallei strain 1026b, kindly provided by Dr.
Don Woods [27,28], was used and prepared as described [23,29–
31]. Pneumonia was induced by intranasal inoculation of a 50 ml
(56101, 2.56102 or 7.56102 colony forming units (CFU)/50 ml)
bacterial suspension. 48 hours after infection, mice were anes-
thetized and sacrificed by bleeding from the vena cava inferior
[23,30,32]. CFUs were determined from serial dilutions of organ
homogenates as described [23,29–31]. In some experiments mice
were injected intraperitoneally with 2 mg of anti-MIF or non-
immune IgG 2 hours before bacterial inoculation or with 50 mg
recombinant mouse MIF or control buffer at the onset of
infection as described previously [16,33,34]. Rabbit polyclonal
anti-MIF and recombinant MIF were generated as described
[16,34].
Murine assays
The ELISA for mMIF developed according to the 4-span
approach was used as described in detail [35]. Tumor necrosis
factor (TNF)-a, interferon (IFN)-c, interleukin (IL)-6, IL-10 and
IL-12p70 were determined using a cytometric bead array (CBA)
multiplex assay in accordance with the manufacturer’s instructions
(BD Biosciences, San Jose, CA).
MIF immunochemistry and histologic examination
Four-mm thick lung tissue sections were sampled 48 hours after
infection and mounted on aminopropylmethoxysilane-coated glass
slides, deparaffinized in xylol, taken through to absolute alcohol
and blocked for endogenous peroxidase with 0.1% hydrogen
peroxide in methanol. They were boiled in 10 mM citrate buffer
in a microwave oven and rinsed in Tris-buffered saline (TBS). To
reduce non-specific binding, sections were incubated in normal
goat serum (Pel-Freez Biologicals, Rogers, AK) 1:30 in TBS. After
40-minutes incubation with polyclonal rabbit anti-MIF purified
IgG diluted 1:200 in TBS containing 2% bovine serum albumin
(final immunoglobulin concentration: 25 mg/l), the sections were
incubated with biotinylated goat anti-rabbit IgG (Vector, Burlin-
game, CA) diluted 1:400 and then with ABC-peroxidase complex
solution (Vector). Peroxidase activity was revealed with 5-59-
diaminobenzidine as chromogen and the sections were counter-
stained in Meyer’s acid-free hematoxylin. As a negative control,
the primary antibody was replaced by pre-immune rabbit purified
IgG. Furthermore, to score inflammation, lung and livers from
infected mice were harvested 48 hours after infection, fixed in
10%-formalin and embedded in paraffin. Four mm sections were
stained with hematoxylin and eosin and analyzed by a pathologist
blinded for groups exactly as described previously [23].
Effect of MIF on bacterial growth in vitro
B. pseudomallei strain 1026b was used and prepared as described
above. In short, B. pseudomallei at concentrations from 36103–
36106 CFU/ml was grown in the presence of recombinant MIF
(dose range from 5 to 50 mg/ml) diluted in LB-growth medium.
Phagocytosis
Phagocytosis was evaluated as described [36,37]. Heat-killed B.
pseudomallei was labeled with carboxyfluorescein-diacetate-succini-
midyl-ester (CFSE dye, Invitrogen, Breda, The Netherlands).
Peritoneal macrophages (derived from 5 different mice per group)
were incubated with CFSE-labeled B. pseudomallei (2.56107 CFU/
ml) for 0, 60 and 120 minutes. Phagocytosis was stopped by
placing cells on ice; thereafter cells were washed in PBS and
suspended in Quenching solution (Orpegen, Heidelberg, Ger-
many). To determine the neutrophil phagocytosis capacity, 50 ml
of whole blood was incubated with bacteria after which cells were
suspended in Quenching solution, incubated in FACS lysis/fix
solution (BecktonDickinson) and neutrophils were labeled using
anti-Gr-1-PE (Pharmingen). Phagocytosis was determined using
FACS.
Author Summary
Melioidosis is a severe tropical infection caused by the
bacterium Burkholderia pseudomallei. B. pseudomallei is the
major cause of community-acquired septicemia in north-
east Thailand with a mortality rate in severe cases of
around 40% Little is known, however, about the mecha-
nisms of the host defense to B. pseudomallei infection.
Macrophage migration inhibitory factor (MIF) is a proin-
flammatory cytokine that has emerged as an important
mediator of the host defense in severe bacterial infections.
In this article, we studied the expression and function of
MIF both in patients with melioidosis and in mice during
experimental melioidosis. We found that MIF concentra-
tions were elevated in patients with melioidosis. Further-
more, high MIF concentrations are associated with poor
outcome in patients with melioidosis. Also, in mice with
experimentally induced melioidosis, we observed an
upregulation of MIF concentrations. Furthermore, mice
with melioidosis that were treated with a MIF blocking
treatment showed lower bacterial counts in their lungs
during infection. In conclusion, MIF seems to impair host
defense mechanisms during melioidosis.
MIF in Melioidosis
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Statistical analysis
Values are expressed as means 6 standard error of the mean
(SEM). Differences between groups were analyzed by Mann-
Whitney U test or Kruskal-Wallis analysis with Dunn’s posthoc
test where appropriate. For survival analysis, Kaplan-Meier
analysis followed by log rank test was performed. These analyses
were performed using GraphPad Prism version 4.00, GraphPad
Software (San Diego, CA). Values of P,0.05 were considered
statistically significant.
Results
MIF expression is elevated in patients with melioidosis
and correlates with poor outcome
To obtain an insight into MIF expression during melioidosis, we
first measured MIF in plasma from 34 patients with culture proven
B. pseudomallei infection and in plasma from 32 local healthy
controls. The mortality rate in this cohort of patients was 44%.
MIF was markedly elevated in melioidosis patients with mean
plasma concentrations that were approximately 2-fold higher than
in those of healthy subjects (Figure 1A, P,0.01). Plasma
concentrations of MIF were associated with an adverse outcome:
on admission patients who went on to had higher MIF
concentrations than those who survived (Figure 1B, P,0.01). In
line, MIF mRNA levels were significantly higher in peripheral
blood leukocytes from patients than in leukocytes from healthy
controls (Figure 1C, P,0.001).
Increased MIF expression in the pulmonary compartment
during experimental pneumonia-derived melioidosis
Since the majority of severe melioidosis cases presents with
pneumonia with bacterial dissemination to distant body sites [19–
21] and considering the fact that it is not feasible to study MIF
expression at tissue level in patients with melioidosis, we used a
well-established murine model of pneumonia-derived melioidosis
in which mice are intranasally infected with B. pseudomallei
[23,29,31]. In agreement with the data obtained in patients with
melioidosis, infected mice showed an abundant upregulation of
MIF expression, both in the pulmonary and systemic compart-
ment (Figure 2, both P,0.01). Immunohistochemical staining of
lung tissue was performed to further identify the distribution of
MIF expression during melioidosis. Positive immunostaining for
MIF was observed in untreated control animals in alveolar
macrophages and within the bronchial epithelium (Figure 3A).
Granulocytes did not stain positive for MIF. After infection with B.
pseudomallei there was a marked increase in immunostaining of the
epithelial submucosa, bronchial epithelial cells and inflammatory
cells, most notably of alveolar macrophages (Figure 3B).
Effect of recombinant MIF treatment on bacterial
outgrowth
To obtain a first insight into the function of MIF during
experimental melioidosis, we treated mice infected with
2.56102 CFU B. pseudomallei mice with 50 mg recombinant MIF
using a dose similar to that used previously in an experimental
septic shock model [16,33]. Treatment of mice with recombinant
MIF at the time of infection resulted in increased MIF
concentrations in lung homogenates 48 hours later (from
3361.3 to 729656.6 ng/ml; P,0.001). Mice were sacrificed
48 hours after inoculation to determine bacterial loads in lungs
(the primary site of the infection), liver and blood (to evaluate to
which extent the infection disseminated to distant body sites)
(Figure 4). Relative to infected but non-treated controls, mice
treated with recombinant MIF displayed almost 10-fold higher
bacterial loads in the liver (Figure 4, P,0.01). In addition, a clear
trend was seen towards higher bacterial loads in the pulmonary
and systemic compartments of recombinant MIF treated mice,
although the differences with control mice did not reach statistical
significance (Figure 4).
Effect of anti-MIF treatment on bacterial outgrowth
Having found that administration of supra physiological doses
of MIF results in a partially impaired bacterial clearance during
experimental melioidosis, we next hypothesized that treatment
with anti-MIF antibodies would result in decreased bacterial
outgrowth and performed the reverse experiment by examining
the effect of anti-MIF treatment. Therefore, before inoculating
mice with B. pseudomallei, we injected mice with anti-MIF
antibodies using a dosing schedule previously found be protective
in a mouse model of E. coli or CLP-induced peritonitis [16,33]. To
evaluate whether anti-MIF treatment interferes with bacterial
clearance, we first determined bacterial loads 48 hours after
infection with an inoculum of 2.56102 CFU B. pseudomallei
(Figure 5). At this dose no significant differences in bacterial
outgrowth in either lungs, liver or blood were observed. To
determine whether the effect of anti-MIF therapy is dependent on
Figure 1. MIF plasma and leukocyte mRNA levels are elevated in melioidosis patients and correlate with poor outcome. In patients
(m, n = 34) with melioidosis, strongly increased plasma concentrations of plasma MIF were present on admission when compared to healthy controls
(&, n = 32) (A). Patients who went on to die from melioidosis had higher MIF plasma concentrations on admission than patients who survived (B).
MIF mRNA was strongly upregulated in the peripheral blood leukocytes of melioidosis patients compared to healthy controls (C). B2M: b2
microglobulin. ** p,0.01; *** p,0.001.
doi:10.1371/journal.pntd.0000605.g001
MIF in Melioidosis
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the size of the infectious dose, we next infected mice with a higher
(56102 CFU B. pseudomallei) and lower (56101 CFU B. pseudomallei)
inoculum (Figure 6). At the highest dose no effect of anti-MIF
treatment was seen on the bacterial outgrowth in the lungs, liver or
blood (Figure 6B). However, at the lowest inoculum mice treated
with anti-MIF had almost 10-fold less B. pseudomallei CFU in their
lungs compared to control mice (Figure 6A, P,0.05). With this low
inoculum, none of the mice showed positive Burkholderia cultures in
liver or blood, suggesting that anti-MIF treatment inhibits the
growth of B. pseudomallei in the lungs after infection with a relatively
low bacterial dose. Lastly, we performed a survival experiment in
which mice were injected intraperitoneally with 2 mg of anti-MIF
or non-immune control IgG 2 hours before intranasal inoculation
with B. pseudomallei. In accordance with the modest protective
effect of anti-MIF treatment on bacterial outgrowth a limited
survival advantage was seen in the anti-MIF treated group
(Figure 7).
Influence of anti-MIF and recombinant MIF on the
inflammatory response
Since cytokines are important regulators of the inflammatory
response to acute lower respiratory tract infection [38] and given
the observation that protective anti-MIF treatment reduced
TNFa concentrations in mouse model of sepsis induced by E.
coli or CLP [16,33], we measured the concentrations of TNFa,
IL-6, IL-10, IL-12 and IFNc in lung homogenates and plasma
obtained 48 after infection with 2.56102 CFU B. pseudomallei
(Table 1). Anti-MIF treatment did not influence pulmonary
cytokine concentrations in our model of experimental melioidosis
(Table 1). Previously it was shown that plasma TNFa
concentrations induced by LPS were lower in MIF-deficient
mice compared to wild-type mice [10,33]. However also in
plasma no differences in TNFa or IL-6, IL-10, IL-12 and IFNc
concentrations were seen between anti-MIF treated and control
mice after inoculation with B. pseudomallei (data not shown). In
addition treatment with 50 mg recombinant MIF did not
influence cytokine concentrations in either the pulmonary
(Table 1) or systemic compartment (data not shown). Consid-
ering that MIF is regarded as an important proinflammatory
mediator, we determined whether modulation of MIF concen-
trations could have an effect on organ inflammation during
experimental melioidosis. Therefore, we performed histopatho-
logical analyses of lung and liver tissues in control mice and mice
treated with anti-MIF or recombinant MIF and infected with B.
pseudomallei. Although all mice showed evidence of inflammation
as characterized by diffuse infiltrates, interstitial inflammation
and bronchitis there were no differences in total organ
histopathological scores between groups (data not shown).
Figure 2. Increased MIF concentrations during experimental melioidosis in mice. Pulmonary MIF expression was strongly increased
72 hours after intranasal inoculation with B. pseudomallei (A). Plasma MIF concentrations remained constant during the first two days of infection,
followed by a steep increase over time (B). Data are means 6 SEM of 5 mice per group at each time point. ** p,0.01 versus t = 0.
doi:10.1371/journal.pntd.0000605.g002
Figure 3. Immunostaining for MIF in the lungs of mice. Positive immunostaining for MIF in lung tissue was observed in non-infected control
animals of bronchial epithelial cells and alveolar macrophages (A). 48 hours after infection with B. pseudomallei there was a marked increase in
immunostaining of the epithelial submucosa, bronchial epithelial cells and inflammatory cells, most notably of alveolar macrophages (B).
Magnification610, insets620.
doi:10.1371/journal.pntd.0000605.g003
MIF in Melioidosis
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No direct effect of MIF on bacterial outgrowth or
phagocytosis
Having found that anti-MIF treated mice showed lower
bacterial loads in their lungs upon infection with a low inoculum
while mice treated with recombinant MIF displayed a modestly
impaired clearance of B. pseudomallei, we next wished to determine
whether MIF has a direct effect on bacterial outgrowth and/or
phagocytosis. Therefore, B. pseudomallei (at concentrations from
36103–36106 CFU/ml) was grown in the presence of recombi-
nant MIF diluted in the growth medium (dose range from 5 to
50 mg/ml). However, no effects of recombinant MIF on bacterial
outgrowth could be observed at any time point (up to 2 hours;
data not shown). Lastly, we studied whether MIF contributes to
phagocytosis of B. pseudomallei. However no effects of anti-MIF
treatment on phagocytosis of B. pseudomallei by peritoneal
macrophages or whole blood neutrophils could be observed (data
not shown).
Discussion
In the present study we aimed to characterize the expression
and role for MIF in melioidosis, linking observational studies in
patients with culture-proven disease with functional studies in mice
in which we modulated the concentrations of MIF during
experimentally induced melioidosis. Our study shows that patients
with severe melioidosis have strongly increased MIF plasma and
MIF mRNA leukocyte levels. High plasma MIF concentrations
were associated with mortality. Similarly, mice intranasally
inoculated with B. pseudomallei displayed a strong increase in
pulmonary and systemic MIF expression. The functional role of
MIF in our model of experimental melioidosis however was
modest given the fact that modulation of MIF levels only
moderately influenced the innate immune response towards B.
pseudomallei. Anti-MIF treatment resulted in a modest survival
benefit. Anti-MIF treatment only decreased bacterial outgrowth
when mice were inoculated with a low dose of B. pseudomallei
whereas - conversely - mice treated with recombinant MIF
displayed a modestly impaired clearance of B. pseudomallei. These
data are the first to report on the expression and function of MIF
during melioidosis.
MIF expression is increased in a wide variety of infectious
diseases, ranging from viral infections, such as Dengue, HIV and
West Nile virus infection [39–41], malaria [42], tuberculosis [43]
and various forms of sepsis [11,12,15]. Our study further extends
these findings by demonstrating increased plasma and blood
leukocyte mRNA levels of MIF in patients with severe melioidosis.
Importantly, we demonstrated a strong association between
elevated MIF levels and increased mortality. This is in line with
a recent study among pediatric and adult patients with severe
sepsis or septic shock caused predominantly by Neisseria meningitides
and other gram-negative bacteria in which elevated MIF levels
were shown to be predictive of early mortality [12]. MIF, however,
is not always upregulated after acute infection or inflammation.
For instance, in children with acute malaria circulating MIF levels
were significantly lower compared with healthy, malaria-exposed
children [44]. Furthermore, MIF release could not be detected in a
human endotoxemia model and is not produced by whole blood
cells incubated with LPS [15]. Also in HIV seropositive patients
low serum MIF levels were associated with a high 1-month
mortality [41]. This further highlights the potential diverse roles
Figure 4. Effect of recombinant MIF on bacterial clearance. Mice, treated with control buffer (white bars) or recombinant MIF (grey bars) and
inoculated with 2.56102 CFU B. pseudomallei intranasally, were analysed for bacterial outgrowth in the lungs (A), liver (B) and blood (C) 48 hours
later. Data represent mean 6 SEM of n = 8 mice per group; ** p,0.01.
doi:10.1371/journal.pntd.0000605.g004
Figure 5. Effect of anti-MIF antibodies on bacterial clearance. Mice were treated with non-immune IgG control (white bars) or anti-MIF
antibodies (grey bars) and inoculated with 2.56102 CFU B. pseudomallei intranasally after which bacterial outgrowth in the lungs (A), liver (B) and
blood (C) was analysed 48 hours later. Data represent mean 6 SEM of n = 8 mice per group.
doi:10.1371/journal.pntd.0000605.g005
MIF in Melioidosis
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MIF can play in the host response against various invading
pathogens.
Melioidosis, which is the most common form of community-
acquired sepsis in Northern-Australia and Eastern-Thailand, is
associated with a mortality of up to 50% in endemic areas [19,20].
Severe pneumonia with bacterial dissemination to distant body
sites is a common presentation of melioidosis [20,21]. Sepsis
caused by B. pseudomallei is characterized by a markedly
proinflammatory cytokine profile; in the current cohort of patients
we have demonstrated increased plasma concentrations of IL-6,
IL-8 and IL-18 when compared to controls [31,45]. In addition,
high throughput mRNA profiling in these patients suffering from
severe melioidosis furthermore demonstrated increased transcrip-
tion of a whole array of proinflammatory genes in whole blood
leukocytes [26]. In light of the proinflammatory properties
attributed to MIF in sepsis, we studied the expression and function
of MIF in a well-established mouse model of melioidosis
[23,29,31]. In line with our patient data and in line with various
other murine models of sepsis induced by LPS, E. coli or CLP
[4,16,46], we observed a strong upregulation of MIF expression in
both the lungs and blood of mice inoculated with B. pseudomallei.
However, MIF seems to play a less important role in the innate
immune response in melioidosis, which is in contrast with previous
studies pointing towards a central role of MIF in other forms of
infection. With regard to bacterial infection, the role of MIF has
been first studied in abdominal sepsis caused by either intraper-
itoneal injection of E. coli or CLP [9,16]. In these models, anti-MIF
from the same source and administered in the exact same dose
protected mice from mortality, reduced TNFa concentrations and
diminished bacterial growth. Very recently it was shown that
polymorphisms associated with higher MIF expression may have a
beneficial effect in community-acquired pneumonia [47]. In
addition, modulation of MIF may have therapeutic advantages
in treating acute lung injury in patients with acute pancreatitis
complicated by bacterial infection [48]. The fact that anti-MIF
only has a minor impact on the immune response to B. pseudomallei
could be related to differences in the primary site of infection and/
or differences in the pathogens involved [9,16]. In this respect it is
worthwhile noting that MIF regulates innate immune responses in
gram-negative infections through modulation of Toll-like receptor
4 [8]. We obtained recent evidence - counter intuitively for a
gram-negative infection - that TLR2 impacts on the immune
response of the intact host in vivo, whereas TLR4 does not
contribute to protective immunity in melioidosis [23]. As such, the
minor role of TLR4 in the innate immune response towards B.
Figure 6. Effect of anti-MIF treatment on bacterial clearance is dependent on the inoculum size. Mice were treated with non-immune
IgG control (white bars) or anti-MIF antibodies (grey bars) and inoculated with 56101 CFU (A) or 56102 CFU (B) B. pseudomallei intranasally after
which bacterial outgrowth in the lungs, liver and blood was analysed 48 hours later. No bacterial outgrowth in the liver and no bacteremia was
observed in any of the mice inoculated with 56101 CFU B. pseudomallei. Data represent mean 6 SEM of n= 8 mice per group; * p,0.05.
doi:10.1371/journal.pntd.0000605.g006
Figure 7. Effect of treatment with anti-MIF antibodies on
survival of mice infected with B. pseudomallei. Mice were injected
intraperitoneally with 2 mg of anti-MIF (straight line with downward
arrow) or non-immune control IgG (dashed line with upward arrow)
2 hours before inoculation with 5.06102 CFU of B. pseudomallei
intranasally; n = 12 mice per group; * p,0.05.
doi:10.1371/journal.pntd.0000605.g007
Table 1. Cytokine concentrations (pg/ml) in lung
homogenates of mice treated with anti-MIF antibodies or
recombinant MIF during experimental melioidosis.
Cytokine
Non-immune
IgG Anti-MIF mAb Control
Recombinant
MIF
TNF-a 26326524 12176475 19106154 28276652
IL-6 24216255 24616242 15306203 21056459
IL-10 97617 10068.3 79613 125615
IL-12p70 9168.6 10867.4 11667.6 116614
IFN-c 4326198 218678.4 366637 3116151
Pulmonary cytokine concentrations after intranasal infection with 2.56102 CFU
B. pseudomallei. Mice were sacrificed 48 hours after infection. Data are means 6
SEM of eight mice per group per time point. TNF-a: tumor-necrosis-factor (TNF)-
a; IL = interleukin; IFN-c = Interferon-c.
doi:10.1371/journal.pntd.0000605.t001
MIF in Melioidosis
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pseudomallei could be an explanation for our present findings
revealing an equally limited role for MIF in melioidosis.
Interestingly, during murine Listeria monocytogenes infection, the
elimination of bacteria from the spleen and liver was not affected
by anti-MIF antibody although this treatment was able to rescue
mice from lethal infection [49].
In reverse experiments we found that treatment of B. pseudomallei
infected mice with recombinant MIF caused impairment of the
bacterial clearance capability. Earlier studies showed that
recombinant MIF increased mortality during E. coli sepsis when
co-injected with bacteria in mice [16,33,50]. In these investiga-
tions the effect of recombinant MIF on bacterial loads was not
reported. These findings imply that increased concentrations of
MIF can be harmful in the acute host response against invading
bacteria. In this respect it is of interest that during the immune
suppressed state which occurs in the late phase of the septic
response and which is characterized by a reduced capacity of
immune cells to produce proinflammatory cytokines such as
TNFa, it was shown that treatment with recombinant MIF could
protect animals from bacterial superinfection in a mouse model of
CLP-induced peritonitis [51]. This further highlights the potential
diverse nature of MIF function during the course of sepsis.
Our study has several limitations. Our observations were done
in patients with sepsis caused by B. pseudomallei and caution is
required when extending these findings to less severe or chronic
melioidosis, since we focused on the early acute phase of
melioidosis. Furthermore, although our in vivo model of melioidosis
has been important in elucidating the role of other inflammatory
mediators in melioidosis [23,29,31], data obtained from a mouse
model by definition should be extrapolated to patients with
melioidosis with great caution. In addition, it would be of interest
to confirm our results in MIF knockout mice, although we
consider it less likely that the use of these mice will yield strongly
different data in light of the modest differences observed in the
different treatment groups. Lastly, obtaining new biological
insights from studies using antibodies and recombinant proteins
of interest remains a challenge, limited by the notion of
considerable cooperation between inflammatory factors involved
and extensive redundancy in the host response against invading
pathogens [52].
In conclusion, MIF concentrations are markedly increased
during melioidosis, and elevated levels correlate with mortality.
Although mice with experimentally induced melioidosis showed
strongly upregulated expression of MIF in lungs and blood,
inhibition of MIF with a specific antibody only modestly
influenced the host response. Similarly, administration of recom-
binant MIF did not strongly impact on the immune response to B.
pseudomallei infection. These data argue against an important role
for MIF in the pathogenesis of melioidosis.
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